Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06216314
Other study ID # 1201202302023
Secondary ID 22HUM-23661
Status Completed
Phase N/A
First received
Last updated
Start date April 20, 2023
Est. completion date July 15, 2023

Study information

Verified date January 2024
Source Universidad Rey Juan Carlos
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study was to compare the performance effects of the intensity demarcation model based on the race pace based approach with the triphasic physiological model and heart rate variability guidelines (HR+HRV)


Description:

After being informed and signing informed consent about the present study, participants were randomly assigned to one of three groups before the intervention phase using a Web-based computer program (www.randomizer.org). Groups were matched on a 1:1:1 basis by gender, age, and performance in an official 10-km race in the previous month. Once selected, participants in the heart rate variability (HRV) group began daily measurements to obtain their personalized parameters. The groups changed according to the intensity zone demarcation pattern: heart rate (HR), race pace (RP) and HR+HRV. The HR group was considered the active control group, as considered the current best practice according to the current literature in endurance running. A 4-week pre-intervention plus 6-week intervention program was set up. Participants were assessed in four different sessions, two for laboratory evaluations and two for time trial performance. The first session consisted of a running economy test, and, after at least half an hour of rest, a maximal incremental treadmill run. They familiarised themselves with the training sessions according to their group (i.e., running based on HR, RP or HR+HRV guidelines, respectively). The HRV4training mobile application (https://www.hrv4training.com) was used to assess HRV for one minute in the morning. The difference in RR intervals between heartbeats is used to calculate HRV. The program then uses this information to calculate the rMSSD and moving average (LnrMSSD7-d), converting the results to a number between 5 and 10. Then, the participant must answer a series of questions including his or her current physical state, sleep quality, muscle soreness, etc. After interpolating these variables, the application shows the subjective value derived from the body's reaction to stresses. As a result, daily indications are given in numerical form, with a range of normality (for HR and HRV) that varies each day depending on how the person reacts to stress. Participants were instructed to take the measurement as soon as they woke up, with an empty bladder, lying down, trying to limit movement, and breathing naturally Training variables (total time, distance, total time spent in each zone) and Training Impulse (TRIMP) were the same for all groups


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date July 15, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Being adults - VO2max between 45 and 60 mL·min-1·kg^-1 for men - VO2max between 40 and 55 mL·min^-1 for women - More than 4 days per week of training frequency - Running experience = 2 years - Record HR data of all training sessions during the study Exclusion Criteria: - Previous injuries for at least three months - Smokers - Any cardiovascular condition that compromises health status and participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Heart rate (HR)
Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
Race pace based approach (RP)
Runners ran respecting three intensity zones. The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test. Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace
Heart rate + heart rate variability (HRV)
Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.

Locations

Country Name City State
Spain Universidad Rey Juan Carlos Fuenlabrada Madrid

Sponsors (2)

Lead Sponsor Collaborator
Universidad Rey Juan Carlos GO fit Lab- Ingesport

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Carrasco-Poyatos M, Gonzalez-Quilez A, Martinez-Gonzalez-Moro I, Granero-Gallegos A. HRV-Guided Training for Professional Endurance Athletes: A Protocol for a Cluster-Randomized Controlled Trial. Int J Environ Res Public Health. 2020 Jul 29;17(15):5465. doi: 10.3390/ijerph17155465. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline of Running Economy Tests were performed on the treadmill and respiratory gas analysis was carried out.
The laboratory tests included:
- Running economy (RE) test (ml·kg·km)
RE was measured by running two blocks at constant speeds (7 and 9 km·h^-1 or 8 and 10 km·h^-1, respectively), depending on the subject's level, intensities below the first ventilatory threshold. Each block lasted three minutes.
RE is one of the physiological determinants of endurance performance: an improvement in RE over time indicates an improvement in performance
Baseline and after 6 weeks
Primary Change from Baseline of VO2max Tests were performed on the treadmill and respiratory gas analysis was carried out.
The laboratory tests included:
- Maximum oxygen consumption test (VO2max)
After 30 minutes of rest, a maximal incremental test was performed to calculate relative VO2max (ml·kg^-1·min^-1) and absolute VO2max (L·min^-1).
The test started at the last speed of the RE test (9 or 10 km·h^-1), depending on the subject's level. The speed increased continuously by 0.5 km·h-1 every minute until exhaustion. The mean value of the last 30 s of the VO2, a respiratory exchange ratio (RER) >1.05, a HR > 95% of the maximum HR, and an RPE > 18 were the variables considered to calculate the VO2max
VO2max is one of the determinants of endurance performance. The relative VO2max is influenced by weight (at equal VO2max, the runner who weighs less is more advantaged). An improvement in absolute and relative values of VO2max over time indicate an improvement in performance
Baseline and after 6 weeks
Primary Change from Baseline of Maximum aerobic velocity (VAM) Tests were performed on the treadmill and respiratory gas analysis was carried out.
The laboratory tests included:
- Maximum aerobic velocity (VAM) in km·h^-1
VAM was calculated as the minimum speed that elicits maximum oxygen consumption.
VAM is one of the physiological determinants of endurance performance. An increase in VAM velocity over time is an indication of improved performance
Baseline and after 6 weeks
Primary Change from Baseline of 7-km Time Trial Performance Before and after 6 weeks, the final time achieved in a 7-km time trial performance was calculated for all participants.
The athletes were instructed to achieve their best performance on the 7-km. The test was performed in a 400m regulation athletic track. Verbal encouragement was given to all runners in both tests every 400-m lap.
Participants used the same shoe model in the two tests and were asked not to use stimulants (coffee, tea, etc.). They performed the tests at the same time of day ± (2 hours).
A decrease in the final time in the second test, indicates an improvement in performance
Baseline and after 6 weeks
Primary Change from Baseline of the First Physiological Thresholds (VT1) Ventilatory thresholds (VT1 and VT2), measured by gas analysis, are some of the determinants of endurance performance, along with running economy and VO2max.
Were measured changes in:
- Velocity associated with the first ventilatory threshold (VT1) in km·h^-1
Velocity zones corresponding to VT1 indicates a low intensity zone. An increase over time in VT1 indicates an improvement of the aerobic system
Baseline and after 6 weeks
Primary Change from Baseline of the second Physiological Thresholds (VT2) Ventilatory thresholds (VT), measured by gas analysis, are some of the determinants of endurance performance, along with running economy and VO2max.
Were measured changes in:
- Velocity associated with the second ventilatory threshold (VT2) in km·h^-1.
Intensity zones corresponding to VT2 indicates a high intensity zone. An increase over time in VT2 indicates an improvement in the anaerobic system
Baseline and after 6 weeks
Primary Change from baseline in HR associated with the first ventilatory threshold Ventilatory thresholds (VT), measured by gas analysis, are some of the determinants of endurance performance, along with running economy and VO2max.
were measured changes in:
- HR associated with the first ventilatory threshold HR-VT1 in beats per minute (bpm).
A lower HR associated with VT1, indicates an improvement of the aerobic system over time
Baseline and after 6 weeks
Primary Change from baseline in HR associated with the second ventilatory threshold Ventilatory thresholds (VT), measured by gas analysis, are some of the determinants of endurance performance, along with running economy and VO2max.
were measured changes in:
- HR associated with the second ventilatory threshold (HR-VT12) in beats per minute (bpm).
Higher HR associated with VT2, indicates an improvement of the anaerobic system over time
Baseline and after 6 weeks
Secondary Change of Rate of Perceived Exertion (RPE) scale after 6 weeks protocol Participants indicated Rating of perceived exertion (RPE) using Borg's 6-20 validated scale, an exertion perception scale used during laboratory testing. RPE values were measured for both the running economy and during the incremental maximal test (VO2max).
The RPE values are:
6. = no exertion at all 7. = extremely light 9. = very light 11. = light 13. = somewhat hard 15. = hard (heavy) 17. = very hard 19. = extremely hard A decrease in RPE over time for the same intensity (e.g., same speed achieved in tests) indicates better performance adaptation
Baseline and after 6 weeks
Secondary Changes in Body Weight Participants were weighed before and after the study to calculate body composition analysis. Participants arrived well hydrated, and were instructed to eat at least two hours beforehand. Weighing was performed at the same time slot (± 2 hours).
it was measured:
- Body weight (kg)
Baseline and after 6 weeks
Secondary Changes in Height (cm) Participants were weighed before and after the study to calculate body composition analysis.
Participants arrived well hydrated, and were instructed to eat at least two hours beforehand. Weighing was performed at the same time slot (± 2 hours).
it was measured:
- Height (cm)
Baseline and after 6 weeks
Secondary Changes in BMI (kg/m^2) Participants were weighed before and after the study to calculate body composition analysis:
Participants arrived well hydrated, and were instructed to eat at least two hours beforehand. Weighing was performed at the same time slot (± 2 hours).
it was measured:
- BMI (kg/m^2)
Baseline and after 6 weeks
Secondary Changes in Fat mass Participants were weighed before and after the study to calculate body composition analysis:
Participants arrived well hydrated, and were instructed to eat at least two hours beforehand. Weighing was performed at the same time slot (± 2 hours).
it was measured:
- Fat mass (%)
Baseline and after 6 weeks
Secondary Changes in Free Fat Mass Participants were weighed before and after the study to calculate body composition analysis:
Participants arrived well hydrated, and were instructed to eat at least two hours beforehand. Weighing was performed at the same time slot (± 2 hours).
it was measured:
- Free fat mass (%)
Baseline and after 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1